Antiviral agent Cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies

Oncogene

Volumn 22, Issue 15, 2003, Pages 2260-2271

  Abdulkarim, Bassam ^a   Sabri, Siham ^b   Zelenika, Diana ^b   Deutsch, Eric ^a   Frascogna, Valerie ^a   Klijanienko, Jerzy ^c   Vainchenker, William ^b   Joab, Irène ^d   Bourhis, Jean ^a,b  

^a Laboratoire UPRES EA 27 10   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSTITUT CURIE   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Apoptosis; Cidofovir; EBV associated cancer; Ionizing radiation; Oncoproteins

Indexed keywords

ANTIVIRUS AGENT; CASPASE 3; CASPASE 9; CIDOFOVIR; MESSENGER RNA; ONCOPROTEIN; ONCOPROTEIN LMP1; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER; CANCER REGRESSION; CANCER THERAPY; CELL LINE; CELL PROLIFERATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; IONIZING RADIATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RADIOSENSITIVITY; RAJI CELL; TOXICITY; VIRUS GENOME; VIRUS INFECTION; VIRUS STRAIN; XENOGRAFT;

ANIMALS; ANTIVIRAL AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BURKITT LYMPHOMA; CARCINOMA; CASPASE 3; CASPASE 9; CASPASES; CELL DIVISION; COMBINED MODALITY THERAPY; CYTOSINE; ENZYME ACTIVATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENES, BCL-2; HERPESVIRUS 4, HUMAN; HUMANS; MICE; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; ONCOGENE PROTEINS, VIRAL; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION TOLERANCE; REMISSION INDUCTION; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; TUMOR VIRUS INFECTIONS; VIRAL MATRIX PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; DNA VIRUSES; HUMAN HERPESVIRUS 4; MUS MUSCULUS;

EID: 0037657521     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1206402     Document Type: Article

References (43)

1. Abbot SD, Rowe M and Cadwallader K. (1990). J. Virol, 64, 2126-2134.
2. Abdulkarim B and Bourhis J. (2001). Lancet Oncol., 2, 622-630.
3. Abdulkarim B, Sabri S, Deutsch E, Chagraoui H, Maggiorella L, Thierry J, Eschwege F, Vainchenker W, Chouaïb S and Bourhis J. (2002). Oncogene, 21, 2334-2346.
4. Balzarini J, Perno CF, Schols D and De Clercq E. (1991). Biochem. Biophys. Res. Commun., 178, 329-335.
5. Busson P, Ganem G and Flores P. (1988). Int. J. Cancer, 42, 599-606.
6. Chung YL, Lee YH, Yen SH and Chi KH. (2000). Clin. Cancer Res., 6, 1452-1458.
7. Dawson CW, Rickinson AB and Young LS. (1990). Nature, 344, 777-780.
8. De Clercq E, Holy A and Rosenberg I. (1996). Nature, 323, 464-467.
9. D'Souza B, Rowe M and Walls D. (2000). J. Virol., 74, 6652-6658.
10. Eliopoulos AG, Blake SM, Floettmann JE, Rowe M and Young LS. (1999). J. Virol., 73, 1023-1035.
11. Eliopoulos AG and Rickinson AB. (1998). Curr. Biol., 8, 196-208.
12. Eliopoulos AG and Young LS. (2001). Semin. Cancer Biol., 11, 435-444.
13. Fagard R, Mouas H, Dusanter-Fourt I, Devillers C, Bissieres P, Martin A, Lenoir G, VanTan H, Feuillard J and Raphael M. (2002). Oncogene, 21, 4473-4480.
14. Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, Falk K, Nilsson E, Yadav M and Busson PI. (1988). Int. J. Cancer, 42, 329-338.
15. Fahraeus R, Jansson A and Ricksten A. (1990). Proc. Natl. Acad. Sci. USA, 87, 7390-7394.
16. Green DR. (2000). Cell 102, 1-4.
17. Gregory CD, Dive C and Henderson S. (1991). Nature, 349, 612-614.
18. Gregory CD, Rowe M and Rickinson AB. (1990). J. Gen. Virol., 71, 1481-1995.
19. Griffin BE. (2000). Mutat. Res., 462, 395-405.
20. Henderson S, Rowe M and Gregory C. (1991). Cell 65, 1107-1115.
21. Hong SY, Yoon WH, Park JH, Kang SG, Ahn JH and Lee TH. (2000). J. Biol. Chem., 275, 18022-18028.
22. Johnson JA and Gangemi JD. (1999). Antimicrob. Agents Chemother., 43, 1198-1205.
23. Kempkes B, Spitkovsky D and Jansen-Durr P. (1995). EMBO. J., 14, 88-96.
24. Kenney JL, Guinness ME, Curiel T and Lacy J. (1998). Blood 92, 1721-1727.
25. Kief E (ed). (1996). EBV and its replication. Field Virology. Fields BN, Knipe DM, Howley PM (eds). Lippincott-Raven: Philadelphia, PA, pp. 2343-2396.
26. Klein G, Giovanella B, Westman A, Stehlin JS and Mumford D. (1975). Intervirology, 5, 319-334.
27. Komano J, Sugiura M and Takada K. (1998). J. Virol., 72, 9150-9156.
28. Laherty CD, Hu HM, Opipari AW, Wang F and Dixit VM. (1992). J. Biol. Chem., 267, 24157-24160.
29. Morgan MB, Goldstein NB and Scadden D. (2000). Tumor Targeting, 4, 278-286.
30. Murray RJ, Wang D and Young LS. (1988). J. Virol., 62, 3747-3755.
31. Neyts J, Sadler R, De Clercq E, Raab-Traub N and Pagano JS. (1998). Cancer Res., 58, 384-388.
32. Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holy A and De Clercq E. (1988). Antimicrob. Agents. Chemother., 32, 1025-1030.
33. Prasad AV, Mohan N, Chandrasekar B and Meltz ML. (1995). Radiat. Res., 143, 263-272.
34. Roth G, Curiel T and Lacy J. (1994). Blood, 84, 582-587.
35. Rowe M, Rowe DT and Gregory CD. (1987). EMBO J., 6, 2743-2751.
36. Shibata D, Weiss LM. (1992). Am. J. Pathol., 140, 769-774.
37. Sinclair AJ, Palmero I, Peters G and Farrell PJ. (1994). EMBO J., 13, 3321-3328.
38. Sung NS, Kenney S, Gutsch D and Pagano JS. (1991). J. Virol., 65, 2164-2169.
39. Wang F, Tsang SF, Kurilla MG, Cohen JI and Kief E. (1990). J. Virol., 64, 3407-3416.
40. Weichselbaum RR, Hallahan D, Fuks Z and Kufe D. (1994). Int. J. Radiat. Oncol. Biol. Phys., 30, 229-234.
41. Weiss LM, Movahed LA, Warnke RA and Sklar J. (1989). N. Engl. J. Med., 320, 502-506.
42. Westphal E, Blackstock W, Feng W, Israel B and Kenney S. (2000). Cancer. Res., 60, 5781-5788.
43. Williams GT. (1991). Cell, 65, 1097-2008.